Vivek Subbiah: When the New England Journal of Medicine publishes a Phase 1 study in any field, you know it’s a game-changer

Vivek Subbiah shared on LinkedIn:

”When the New England Journal of Medicine publishes a Phase 1 study in any field, you know it’s a game-changer!

• Exciting breakthrough in the fight against hereditary angioedema!
• A first-in-human study published in NEJM showcases NTLA-2002, an in vivo gene-editing therapy using CRISPR technology to target the KLKB1 gene.
• Promising results include robust and lasting reductions in plasma kallikrein levels after just a SINGLE dose, paving the way for lifelong control of angioedema attacks.”

Read further.
Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.